Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Singapore SC...

    Singapore SC Disallowes Harish Salve to represent Ranbaxy Owners in Daiichi Case

    Written by savita thakur thakur Published On 2017-02-24T10:32:43+05:30  |  Updated On 24 Feb 2017 10:32 AM IST
    Singapore SC Disallowes Harish Salve to represent Ranbaxy Owners in Daiichi Case

    NEW DELHI: The Singapore Supreme Court has disallowed senior advocate Harish Salve from appearing on behalf of corporate sellers of Ranbaxy against the case filed by the Daiichi Sankyo for not revealing risks involved in the buyout by Ranbaxy owners.


    Earlier, the arbitration court in Singapore directed former promoters of Ranbaxy laboratories Ltd, Malvinder Mohan Singh and Shivinder Mohan Singh to pay damages worth Rs.2,562.78 crore to Japan’s Daiichi Sankyo Co. Ltd.


    Read also: Ex-Ranbaxy owners to pay Rs 2,600 Crores to Daiichi for concealing facts


    Daiichi had filed a case case against former Ranbaxy promoters Malvinder Singh and Shivinder Singh, where the Japanese firm stated that the Former Ranbaxy promoters had concealed relevant information while selling their majority stake to Daiichi in 2008.


    The sellers are seeking to have the award either set aside or a reduction in the quantum, through the appeal. Daiichi, on the other hand, has applied to the court to have the award enforced.


    Seeking permission for representing the Ranbaxy's case, Harish Salve has filed an application in Singapore Supreme Court. He also mentioned his ample experience in this field to argue for an exception to be made in this case as he has been appeared earlier for the brothers in the Delhi High Court.


    On February 17, 2017 the Singapore court has rejected salve's application for appearing in the Singapore court. The Singapore Court has given reasons for not allowing him against the said case. The court said, that no questions of Indian law were involved at this stage. Even at an earlier stage when issues related to the Indian law had arisen, the sellers had employed senior counsel from Singapore, the court noted, and only led evidence from Indian law experts to defend their cases, reports ET


    According to the Section 15 of the Legal Profession Act of Singapore, which contains the conditions that need to be fulfilled before a foreign lawyer is admitted to argue, reports Bar & Bench. Among those conditions is that the applicant should be a Queen’s Counsel, or have an equivalent distinction. “Special qualifications or experience for the purpose of the case” also needs to be established. In view of this provision, the court held,



    “The overarching principle guiding the exercise of the court’s discretion is that foreign senior counsel should only be admitted on the basis of “need”. “Need” should be assessed not only from the perspective of the litigant but also with regard to the court’s need for assistance with the issues in contention.”

    The court further stated that foreign lawyers could be allowed in specific cases, but observed the party seeking to engage them has to first prove that such law was involved in the case, before pressing for counsel from that country.


    Read also: Daiichi Sankyo closes RnD Division in India


    daiichiDaiichi SankyoDelhi high courtHarish SalveMalvinder SinghRanbaxyranbaxy caseRejectedShivinder SinghSingapore Supreme Court
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok